ATE421889T1 - Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen - Google Patents

Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen

Info

Publication number
ATE421889T1
ATE421889T1 AT02711288T AT02711288T ATE421889T1 AT E421889 T1 ATE421889 T1 AT E421889T1 AT 02711288 T AT02711288 T AT 02711288T AT 02711288 T AT02711288 T AT 02711288T AT E421889 T1 ATE421889 T1 AT E421889T1
Authority
AT
Austria
Prior art keywords
decoy
ets
pharmaceutical compositions
containing pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
AT02711288T
Other languages
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Tomio Kawasaki
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE421889T1 publication Critical patent/ATE421889T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/13Decoys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
AT02711288T 2002-02-01 2002-02-01 Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen ATE421889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2002/000865 WO2003063911A1 (fr) 2002-02-01 2002-02-01 Compositions pharmaceutiques contenant un leurre et procede d'utilisation

Publications (1)

Publication Number Publication Date
ATE421889T1 true ATE421889T1 (de) 2009-02-15

Family

ID=27639283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02711288T ATE421889T1 (de) 2002-02-01 2002-02-01 Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen

Country Status (6)

Country Link
US (5) US20040072726A1 (de)
EP (1) EP1470826B1 (de)
JP (1) JPWO2003063911A1 (de)
AT (1) ATE421889T1 (de)
DE (1) DE60231063D1 (de)
WO (1) WO2003063911A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
TWI308492B (de) * 2001-02-20 2009-04-11 Anges Mg Inc
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1799271A4 (de) * 2004-09-21 2010-05-05 Anesiva Inc Abgabe von polynucleotiden
EP1803811B1 (de) * 2004-10-22 2011-05-11 AnGes MG, Inc. Chimäre (doppel-) attrappe
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1892293A4 (de) * 2005-06-06 2008-12-10 Anges Mg Inc Transkriptionsfaktorköder
CA2634291A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
US20100105762A1 (en) * 2007-02-16 2010-04-29 Ryuichi Morishita Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
NZ599881A (en) * 2009-12-03 2014-01-31 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
ES2753274T5 (es) * 2015-08-21 2023-05-26 42 Life Sciences Gmbh & Co Kg Composición y procedimiento de hibridación
WO2018067165A1 (en) * 2016-10-07 2018-04-12 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
CN114304053A (zh) * 2021-12-10 2022-04-12 广东金石医疗科技服务有限公司 一种兔动脉瘤模型的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
PT824918E (pt) * 1995-05-12 2007-06-22 Anges Mg Inc Tratamento e prevenção para doenças causadas pelo nf-kb
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6271206B1 (en) * 1996-09-12 2001-08-07 Valentis, Inc. Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスMg株式会社 脳保護剤
CN100532559C (zh) 2000-02-02 2009-08-26 安增子摩祺株式会社 用于基因转移的病毒包膜载体
US6936468B2 (en) 2000-04-28 2005-08-30 University Of Pittsburgh Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
JP4346233B2 (ja) 2000-12-27 2009-10-21 アンジェスMg株式会社 デコイを含む薬学的組成物およびその使用方法
EP1355907A1 (de) * 2001-01-31 2003-10-29 Pfizer Products Inc. "thiazolyl-, oxazolyl-, pyrrolyl- und imidazolyl-säureamidderivate, die sich als inhibitoren von pde4-isozymen eignen"

Also Published As

Publication number Publication date
US20070142314A1 (en) 2007-06-21
WO2003063911A1 (fr) 2003-08-07
US7524830B2 (en) 2009-04-28
US8067388B2 (en) 2011-11-29
US20100331395A1 (en) 2010-12-30
US20060263422A1 (en) 2006-11-23
US20040072726A1 (en) 2004-04-15
EP1470826B1 (de) 2009-01-28
DE60231063D1 (de) 2009-03-19
EP1470826A1 (de) 2004-10-27
EP1470826A4 (de) 2005-05-25
JPWO2003063911A1 (ja) 2006-01-19
US20040109843A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
ATE421889T1 (de) Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen
ITRM20020596A0 (it) Protesi vascolare ad impianto con tecnica combinata, laparoscopica edendovascolare, per la cura degli aneurismi dell'aorta addominale, e co
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
PT1183015E (pt) Pastilha em multicamadas para administracao de uma combinacao fixa de tramadol e diclofenac
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
ATE448812T1 (de) Beschichtung von stents mit verzögerter wirkstofffreisetzung
HUP0402594A2 (hu) Rapamycint és származékait tartalmazó hatóanyag-leadó rendszerek érbetegségek megelőzésére és kezelésére
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
UA86344C2 (ru) Способ лечения сосудистых заболеваний
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
WO2006047378A3 (en) Biocompatible and hemocompatible amphiphilic coatings for drug deliver
DE602004008304D1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DK1220852T3 (da) Substituerede diazepaner
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
DE69630974D1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
WO2002083074A3 (en) Methods for the treatment of hepatic disorders
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
CY1105308T1 (el) Θepαπεια για υπep-ουρικαιμια
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
AP2004003113A0 (en) Use of an inhibitor or antagonist against tissue factor
NO20050933L (no) Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties